InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing to Accelerate Its Clinical Development and Strengthen Translational Capabilities

NANJING, China, Sept. 3, 2020 /PRNewswire/ -- InxMed (Nanjing) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, today announced the completion of its Series A+ financing of 130M RMB...

from PR Newswire: https://ift.tt/32T1qD3